

# Paul Nankivell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9414405/publications.pdf>

Version: 2024-02-01

40  
papers

1,652  
citations

566801

15  
h-index

301761

39  
g-index

43  
all docs

43  
docs citations

43  
times ranked

3670  
citing authors

#	ARTICLE	IF	CITATIONS
1	A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma. <i>Journal of Pathology</i> , 2022, 256, 174-185.	2.1	20
2	Symptom-based remote assessment in post-treatment head and neck cancer surveillance: A prospective national study. <i>Clinical Otolaryngology</i> , 2022, 47, 561-567.	0.6	2
3	Exploring the views of patients' and their family about patient-initiated follow-up in head and neck cancer: A mixed methods study. <i>European Journal of Cancer Care</i> , 2022, 31, .	0.7	3
4	Pretreatment High $\alpha$ -M2 as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer. <i>Laryngoscope</i> , 2021, 131, E836-E845.	1.1	14
5	Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 66-78.	0.8	165
6	The impact of nodal status in major salivary gland carcinoma: A multicenter experience and proposal of a novel N-classification. <i>Oral Oncology</i> , 2021, 112, 105076.	0.8	20
7	Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA. <i>Epigenomes</i> , 2021, 5, 6.	0.8	10
8	Differential Expression of Potential Biomarkers of Oral Squamous Cell Carcinoma Development. <i>Head and Neck Pathology</i> , 2021, 15, 1127-1136.	1.3	2
9	Civilian Penetrating Neck Trauma at a Level I Trauma Centre: A Five-Year Retrospective Case Note Review. <i>Clinical Otolaryngology</i> , 2021, 47, 44.	0.6	1
10	Development and validation of an improved classification and risk stratification system for carotid body tumors: Multinational collaborative cohort study. <i>Head and Neck</i> , 2021, 43, 3448-3458.	0.9	4
11	Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113854.	6.6	12
12	Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery. <i>Cancers</i> , 2021, 13, 5519.	1.7	6
13	Prognostic indicators in clinically node-negative malignant primary salivary tumours of the parotid: A multicentre experience. <i>Oral Oncology</i> , 2021, 123, 105577.	0.8	3
14	The diagnostic value of cytology in parotid Warthin's tumors: international multicenter series. <i>Head and Neck</i> , 2020, 42, 522-529.	0.9	13
15	Delaying surgery for patients with a previous SARS-CoV-2 infection. <i>British Journal of Surgery</i> , 2020, 107, e601-e602.	0.1	96
16	Safety and 30-day outcomes of tracheostomy for COVID-19: a prospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2020, 125, 872-879.	1.5	96
17	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8229.	1.8	7
18	Conservative management of oesophageal soft food bolus impaction. <i>The Cochrane Library</i> , 2020, 2020, CD007352.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Prioritisation of research topics for head and neck cancer in Africa – Report of the International Collaboration On Improving Cancer outcomes in low and middle income countries – ICoNIC Africa. Oral Oncology, 2020, 102, 104503.	0.8	2
20	The diagnostic value of cytology in parotid Warthin's tumors: International multicenter series. Head and Neck, 2020, 42, 2215-2216.	0.9	5
21	Patient advocacy in head and neck cancer: Realities, challenges and the role of the multi-disciplinary team. Clinical Otolaryngology, 2020, 45, 437-444.	0.6	4
22	Definition of locally recurrent head and neck squamous cell carcinoma: a systematic review and proposal for the Odense–Birmingham definition. European Archives of Oto-Rhino-Laryngology, 2020, 277, 1593-1599.	0.8	19
23	Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects. Cancers, 2019, 11, 1115.	1.7	28
24	Factors affecting prognosis in locoregional recurrence of oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2019, 48, 206-213.	1.4	14
25	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	6.3	697
26	Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncology, 2019, 88, 145-152.	0.8	40
27	Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head and Neck, 2018, 40, 1598-1604.	0.9	34
28	The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England. Oral Oncology, 2018, 85, 40-43.	0.8	4
29	Surveillance of HPV-Positive Head and Neck Squamous Cell Carcinoma with Circulating and Salivary DNA Biomarkers. Critical Reviews in Oncogenesis, 2018, 23, 235-245.	0.2	8
30	Tympanoplasty for Chronic Tympanic Membrane Perforation in Children. Otology and Neurotology, 2015, 36, 796-804.	0.7	106
31	Do corticosteroids improve outcomes in peritonsillar abscess?. Laryngoscope, 2015, 125, 537-538.	1.1	7
32	The presentation, natural history and outcome of T1 a/b thyroid cancer with regard to new grading systems. European Archives of Oto-Rhino-Laryngology, 2015, 272, 439-444.	0.8	2
33	Re-operative thyroid surgery: a 20-year prospective cohort study at a tertiary referral centre. European Archives of Oto-Rhino-Laryngology, 2015, 272, 1503-1508.	0.8	26
34	Investigation of p16 <sup>INK4a</sup> as a prognostic biomarker in oral epithelial dysplasia. Journal of Oral Pathology and Medicine, 2014, 43, 245-249.	1.4	13
35	The binary oral dysplasia grading system: validity testing and suggested improvement. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 87-94.	0.2	63
36	Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia. British Journal of Cancer, 2013, 109, 2864-2874.	2.9	24

#	ARTICLE	IF	CITATIONS
37	Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. <i>Head &amp; Neck Oncology</i> , 2012, 4, 40.	2.3	6
38	Oral Dysplasia: Biomarkers, Treatment, and Follow-up. <i>Current Oncology Reports</i> , 2011, 13, 145-152.	1.8	45
39	Biomarkers in laryngeal dysplasia: A systematic review. <i>Head and Neck</i> , 2011, 33, 1170-1176.	0.9	26
40	COREC Model Information: Can Patients Read What COREC Wants Us to Give Them?. <i>Research Ethics</i> , 2007, 3, 22-23.	0.8	1